Revolution Medicines, Inc. RVMD
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M | $43.0M | $50.0M | $20.2M | — |
| R&D | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M | $132.3M | $91.8M | $51.1M | — |
| SG&A | $195.0M | $97.3M | $75.6M | $40.6M | $30.4M | $21.4M | $12.4M | $9.4M | — |
| Total operating expenses | $1.18B | $689.5M | $498.8M | $293.7M | $217.4M | $153.7M | $104.2M | $60.5M | — |
| Operating income | -$1.18B | -$689.5M | -$487.2M | -$258.3M | -$188.0M | -$110.7M | -$54.1M | -$40.3M | — |
| Interest expense | $24.2M | $0 | $0 | $0 | $12.0K | $71.0K | $106.0K | $116.0K | — |
| Pre-tax income | -$1.13B | -$600.8M | -$439.9M | -$249.1M | -$187.1M | -$108.5M | -$52.0M | -$41.8M | — |
| Income tax | $0 | $753.0K | $3.5M | $420.0K | $0 | $371.0K | $4.4M | — | — |
| Net income | -$1.13B | -$600.0M | -$436.0M | -$249.0M | -$187.0M | -$108.2M | -$47.7M | -$41.8M | — |
| EPS, basic | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | — | — | — |
| EPS, diluted | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 | -21.24 | — |
| Shares, diluted (wtd. avg.) | $190.1M | $167.7M | $113.1M | $80.6M | $72.8M | $54.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M | $104.3M | $16.7M | $69.6M | — |
| Short-term investments | $1.64B | $1.75B | $1.16B | $483.5M | $468.6M | $336.5M | $106.1M | — | — |
| Total current assets | $2.08B | $2.33B | $1.88B | $660.2M | $589.8M | $454.1M | $134.0M | — | — |
| Property, plant and equipment | $33.2M | $24.3M | $22.9M | $18.7M | $11.5M | $8.9M | $7.1M | — | — |
| Goodwill | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | — | — |
| Other intangibles | $55.8M | $56.7M | $57.7M | $58.8M | $59.9M | $60.9M | $62.0M | — | — |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738.0M | $567.4M | $220.5M | — | — |
| Accounts payable | $64.6M | $54.4M | $61.8M | $21.3M | $14.1M | $12.6M | $11.4M | — | — |
| Total current liabilities | $290.4M | $163.9M | $143.9M | $62.0M | $60.4M | $47.2M | $43.1M | — | — |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M | $92.7M | $68.0M | — | — |
| Retained earnings | -$2.87B | -$1.74B | -$1.14B | -$701.3M | -$452.6M | -$265.5M | -$157.4M | — | — |
| Total equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M | $474.7M | -$152.6M | -$108.4M | -$67.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M | -$100.1M | -$49.6M | $1.2M | — |
| Depreciation and amortisation | $7.8M | $6.6M | $5.0M | $4.0M | $3.1M | $2.6M | $2.3M | $1.6M | — |
| Stock-based compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M | $8.9M | $3.2M | $855.0K | — |
| Capital expenditure | $16.0M | $10.3M | $7.7M | $10.8M | $6.5M | $2.9M | $2.6M | $1.5M | — |
| Investing cash flow | $118.1M | -$554.4M | -$342.6M | -$24.1M | -$142.1M | -$234.2M | -$102.0M | -$1.3M | — |
| Financing cash flow | $621.5M | $959.4M | $1.23B | $301.4M | $294.2M | $422.8M | $98.7M | $60.8M | — |
| Dividends paid | — | — | — | — | — | $0 | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182453.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |
| HALO | HALOZYME THERAPEUTICS, INC. | $12.51B | 43.0x | 37.6% |